Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies
The fight against coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 infection is
still raging. However, the pathophysiology of acute and post-acute manifestations of COVID …
still raging. However, the pathophysiology of acute and post-acute manifestations of COVID …
Endothelial dysfunction in COVID-19: a position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic …
The COVID-19 pandemic is an unprecedented healthcare emergency causing mortality and
illness across the world. Although primarily affecting the lungs, the SARS-CoV-2 virus also …
illness across the world. Although primarily affecting the lungs, the SARS-CoV-2 virus also …
Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID)
ACB Lemos, DA do Espírito Santo, MC Salvetti… - Thrombosis research, 2020 - Elsevier
Abstract Introduction Coronavirus disease 2019 (COVID-19) causes a hypercoagulable
state. Several autopsy studies have found microthrombi in pulmonary circulation. Methods In …
state. Several autopsy studies have found microthrombi in pulmonary circulation. Methods In …
COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects
DM Smadja, SJ Mentzer, M Fontenay, MA Laffan… - Angiogenesis, 2021 - Springer
Abstract Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) is presenting as a systemic disease associated with …
syndrome coronavirus 2 (SARS-CoV-2) is presenting as a systemic disease associated with …
Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality
Abstract Background Coronavirus disease 2019 (COVID-19) is a respiratory disease
associated with endotheliitis and microthrombosis. Objectives To correlate endothelial …
associated with endotheliitis and microthrombosis. Objectives To correlate endothelial …
Anticoagulants for people hospitalised with COVID‐19
RLG Flumignan, VT Civile… - Cochrane Database …, 2022 - cochranelibrary.com
Background The primary manifestation of coronavirus disease 2019 (COVID‐19) is
respiratory insufficiency that can also be related to diffuse pulmonary microthrombosis and …
respiratory insufficiency that can also be related to diffuse pulmonary microthrombosis and …
Pathophysiological mechanisms of thrombosis in acute and long COVID-19
H Jing, X Wu, M Xiang, L Liu, VA Novakovic… - Frontiers in …, 2022 - frontiersin.org
COVID-19 patients have a high incidence of thrombosis, and thromboembolic complications
are associated with severe COVID-19 and high mortality. COVID-19 disease is associated …
are associated with severe COVID-19 and high mortality. COVID-19 disease is associated …
Guidance for the management of patients with vascular disease or cardiovascular risk factors and COVID-19: position paper from VAS-European independent …
GT Gerotziafas, M Catalano, MP Colgan… - Thrombosis and …, 2020 - thieme-connect.com
COVID-19 is also manifested with hypercoagulability, pulmonary intravascular coagulation,
microangiopathy, and venous thromboembolism (VTE) or arterial thrombosis. Predisposing …
microangiopathy, and venous thromboembolism (VTE) or arterial thrombosis. Predisposing …
Platelet activation in critically ill COVID-19 patients
Background Microvascular, arterial and venous thrombotic events have been largely
described during severe coronavirus disease 19 (COVID-19). However, mechanisms …
described during severe coronavirus disease 19 (COVID-19). However, mechanisms …
Anticoagulant interventions in hospitalized patients with COVID‐19: A scoping review of randomized controlled trials and call for international collaboration
T Tritschler, ME Mathieu, L Skeith… - … of thrombosis and …, 2020 - Wiley Online Library
Abstract Introduction Coronavirus disease (COVID‐19) is associated with a high incidence
of thrombosis and mortality despite standard anticoagulant thromboprophylaxis. There is …
of thrombosis and mortality despite standard anticoagulant thromboprophylaxis. There is …